Abstract | STUDY OBJECTIVE: DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: Outpatient clinic. PATIENTS: Forty-four patients with documented premature CHD, defined as confirmed myocardial infarction and/or angiographically determined stenosis of 50% or greater in at least one major coronary artery before age 60 years. INTERVENTIONS: Patients were block randomized on the basis of age, gender, and screening Lp(a) concentrations to receive ascorbate 4.5 g/day or placebo for 12 weeks. MEASUREMENTS AND MAIN RESULTS: High-dose ascorbate was well tolerated and produced a marked elevation in mean plasma ascorbate levels (+1.2 mg/dl; p < 0.001). Multiple linear regression analysis revealed no significant effect of supplementation on postintervention Lp(a) levels (p = 0.39) in a model that included treatment group assignment, and baseline Lp(a) levels. CONCLUSIONS: Our findings do not support a clinically important lowering effect of high-dose ascorbate on plasma Lp(a) in patients with premature CHD.
|
Authors | A G Bostom, A L Hume, C B Eaton, J P Laurino, L R Yanek, M S Regan, W H McQuade, W Y Craig, G Perrone, P F Jacques |
Journal | Pharmacotherapy
(Pharmacotherapy)
1995 Jul-Aug
Vol. 15
Issue 4
Pg. 458-64
ISSN: 0277-0008 [Print] United States |
PMID | 7479198
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Lipoprotein(a)
- Ascorbic Acid
|
Topics |
- Ascorbic Acid
(administration & dosage, pharmacology)
- Coronary Disease
(blood)
- Double-Blind Method
- Female
- Food, Fortified
- Humans
- Lipoprotein(a)
(blood)
- Male
- Middle Aged
- Time Factors
|